The stock's fall snapped a three-day winning streak.

“In the end," Vrabel said. "It was clear to me, and to my family, and my soul, that this was the place that I wanted to be.” ...

Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...

Eli Lilly has asked the U.S. government to pause price negotiations for prescription drugs, Bloomberg News reported on Monday ...

U.S. drugmaker Pfizer is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that ...

Eli Lilly (LLY) expects that its experimental weight loss pill will get approved as soon as early next year, CEO David Ricks said in an ...

The risk of developing dementia may be much higher than previously thought, a study published Monday in the journal Nature ...

Pills would be more convenient for patients and also easier to manufacture at large scale than other top weight-loss drugs, which require , CEO Dave Ricks said.

Eli Lilly (LLY) has reportedly asked the Biden administration to pause negotiations with drugmakers over pricing, citing ...

Eli Lilly has asked the U.S. government to pause the new law that allows Medicare to negotiate prices for its costliest ...

And GSK said it would pay up to $1.15 billion privately-held IDRx, a clinical-stage biopharmaceutical company developing therapeutics for the treatment of GIST, which stands for Gastrointestinal ...

The Indianapolis-based drugmaker will acquire Scorpion’s STX-478, a once-daily oral treatment in early trials for breast cancer and other advanced solid tumors.